{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:24:21Z","timestamp":1774891461230,"version":"3.50.1"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,29]]},"DOI":"10.18632\/oncotarget.12876","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T19:49:05Z","timestamp":1480362545000},"page":"79637-79653","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic efficacy of the bromodomain inhibitor OTX015\/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes"],"prefix":"10.18632","volume":"7","author":[{"given":"Michela","family":"Boi","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The AIRC 5xMille Consortium \u2018Genetics-Driven Targeted Management of Lymphoid Malignancies\u2019","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Todaro","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Vurchio","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao Ning","family":"Yang","sequence":"additional","affiliation":[{"name":"Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Moon","sequence":"additional","affiliation":[{"name":"Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Kwee","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland"},{"name":"Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Pan","sequence":"additional","affiliation":[{"name":"Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA"},{"name":"Institute for Precision Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Crescenzo","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"In Vitro Pharmacology, Merck Research Laboratory, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Cerchietti","sequence":"additional","affiliation":[{"name":"Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[{"name":"Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA"},{"name":"Institute for Precision Medicine, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Riveiro","sequence":"additional","affiliation":[{"name":"Oncology Therapeutic Development, Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Cvitkovic","sequence":"additional","affiliation":[{"name":"Oncology Therapeutic Development, Clichy, France"},{"name":"Oncoethix SA (Now Oncoethix GmbH, A Wholly Owned Subsidiary of Merck Sharp & Dohme Corp.), Lucerne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA"},{"name":"Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing","volume":"117","author":"Vasmatzis","year":"2011","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Acquaviva","year":"2015","journal-title":"Cancer Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2014-12-614503","article-title":"Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts","volume":"127","author":"Barreca","year":"2016","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Piris","year":"2013","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOH.0b013e3283623c07","article-title":"Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma","volume":"20","author":"Inghirami","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Inghirami","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-08-1808","article-title":"Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma","volume":"69","author":"Vega","year":"2009","journal-title":"Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in anaplastic large-cell lymphoma","volume":"364","author":"Pogliani","year":"2011","journal-title":"The New England journal of medicine"},{"key":"9","doi-asserted-by":"publisher","first-page":"25064","DOI":"10.18632\/oncotarget.7853","article-title":"Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities","volume":"7","author":"Inghirami","year":"2016","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2015.05.010","article-title":"Anaplastic lymphoma kinase inhibitors","volume":"23","author":"Inghirami","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","article-title":"Interplay between the cancer genome and epigenome","volume":"153","author":"Laird","year":"2013","journal-title":"Cell"},{"key":"12","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-14-2020","article-title":"Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice","volume":"20","author":"Bates","year":"2014","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Chiang","year":"2007","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbagrm.2014.03.011","article-title":"The bromodomain: from epigenome reader to druggable target","volume":"1839","author":"Zhou","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cmdc.201300434","article-title":"Bromodomains and their pharmacological inhibitors","volume":"9","author":"Weinmann","year":"2014","journal-title":"Chem Med Chem"},{"key":"16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"McKeown","year":"2011","journal-title":"Cell"},{"key":"17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Lugo","year":"2011","journal-title":"Nature"},{"key":"18","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Sims","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.1073\/pnas.1216363109","article-title":"Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins","volume":"109","author":"Varmus","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Benes","year":"2013","journal-title":"Cancer Discov"},{"key":"21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs","volume":"21","author":"Stussi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Dombret","year":"2015","journal-title":"Oncotarget"},{"key":"24","article-title":"Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition","author":"Heukamp","year":"2015","journal-title":"Clin Cancer Res"},{"key":"25","first-page":"12","article-title":"Development of the BET bromodomain inhibitor OTX015","author":"Daibata","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4161\/cc.6.16.4554","article-title":"P-TEFb is a crucial co-factor for Myc transactivation","volume":"6","author":"Lania","year":"2007","journal-title":"Cell cycle"},{"key":"27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2008.20.9759","article-title":"Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms","volume":"28","author":"Geissinger","year":"2010","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2005-05-2125","article-title":"Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas","volume":"107","author":"Inghirami","year":"2006","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-11-0776","article-title":"CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers","volume":"11","author":"Ator","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"30","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0609699104","article-title":"Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists","volume":"104","author":"Toftgard","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Chott","year":"2006","journal-title":"Leukemia"},{"key":"32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imr.12248","article-title":"malignancies AxcG-dtmol. Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications","volume":"263","author":"Pileri","year":"2015","journal-title":"Immunol Rev"},{"key":"33","article-title":"The BET bromodomain inhibitor OTX015 (MK-8628) in mantle cell lymphoma (MCL): in vivo activity and identification of novel combinations to overcome adaptive resistance","author":"Bertoni","year":"2015","journal-title":"Molecular Cancer Therapeutic"},{"key":"34","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ferrer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"35","article-title":"A phase 1 dose-finding and pharmacokinetic study of the BET bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma","author":"Lokiec","year":"2016","journal-title":"Lancet Hematology"},{"key":"36","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Weinstock","year":"2012","journal-title":"Blood"},{"key":"37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","article-title":"c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells","volume":"123","author":"Kelliher","year":"2014","journal-title":"Blood"},{"key":"38","first-page":"170","article-title":"New Approaches to Target T-ALL","volume":"4","author":"Stegmaier","year":"2014","journal-title":"Front Oncol"},{"key":"39","article-title":"Bromodomain and extraterminal inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","author":"Michallet","year":"2016","journal-title":"Lancet Hematology"},{"key":"40","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2014-08-598037","article-title":"BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice","volume":"125","author":"Reddy","year":"2015","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1084\/jem.20130376","article-title":"BET bromodomain inhibition suppresses TH17-mediated pathology","volume":"210","author":"Lora","year":"2013","journal-title":"J Exp Med"},{"key":"42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm1249","article-title":"Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target","volume":"11","author":"Inghirami","year":"2005","journal-title":"Nature medicine"},{"key":"43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Chicas","year":"2011","journal-title":"Nature"},{"key":"44","first-page":"297868","article-title":"Itk: the rheostat of the T cell response","volume":"2011","author":"Tsoukas","year":"2011","journal-title":"Journal of signal transduction"},{"key":"45","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Frissora","year":"2013","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Kennedy","year":"2012","journal-title":"J Clin Oncol"},{"key":"47","first-page":"re6","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Engelman","year":"2013","journal-title":"Science signaling"},{"key":"48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-015-0327-6","article-title":"Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies","volume":"55","author":"Riveiro","year":"2016","journal-title":"Clinical pharmacokinetics"},{"key":"49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Shipman","year":"1990","journal-title":"Antiviral research"},{"key":"50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.2237417","article-title":"Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells","volume":"250","author":"Dalla-Favera","year":"1990","journal-title":"Science"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:32:08Z","timestamp":1594830728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":50,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2016,11,29]]}},"alternative-id":["12876","27793034"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12876","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,25]]}}}